These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of alteplase in the treatment of acute ischemic stroke. Micieli G; Marcheselli S; Tosi PA Vasc Health Risk Manag; 2009; 5(1):397-409. PubMed ID: 19475777 [TBL] [Abstract][Full Text] [Related]
5. A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-Trial. Zinkstok SM; Vermeulen M; Stam J; de Haan RJ; Roos YB; Trials; 2010 May; 11():51. PubMed ID: 20459856 [TBL] [Abstract][Full Text] [Related]
6. Role of tissue plasminogen activator in acute ischemic stroke. Hatcher MA; Starr JA Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027 [TBL] [Abstract][Full Text] [Related]
7. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Demaerschalk BM; Kleindorfer DO; Adeoye OM; Demchuk AM; Fugate JE; Grotta JC; Khalessi AA; Levy EI; Palesch YY; Prabhakaran S; Saposnik G; Saver JL; Smith EE; Stroke; 2016 Feb; 47(2):581-641. PubMed ID: 26696642 [TBL] [Abstract][Full Text] [Related]
8. Intravenous Recombinant Tissue Plasminogen Activator Does Not Impact Mortality in Acute Ischemic Stroke at Any Time Point up to 6 Months: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. Kumar G; Uhrig D; Fowler S; DeLaney MC; Alexandrov AV CNS Drugs; 2015 Aug; 29(8):659-67. PubMed ID: 26251162 [TBL] [Abstract][Full Text] [Related]
10. Acute onset internuclear ophthalmoplegia responsive to treatment with intravenous alteplase. Mahawish KM; Aravind A N Z Med J; 2020 May; 133(1515):119-121. PubMed ID: 32438384 [No Abstract] [Full Text] [Related]
11. Utilization of Intravenous Tissue Plasminogen Activator and Reasons for Nonuse in Acute Ischemic Stroke in Saudi Arabia. Al Khathaami AM; Al Bdah B; Tarawneh M; Alskaini M; Alotaibi F; Alshalan A; Almuhraj M; Aldaham D; Alotaibi N J Stroke Cerebrovasc Dis; 2020 May; 29(5):104761. PubMed ID: 32173225 [TBL] [Abstract][Full Text] [Related]
12. Alteplase Therapy for Acute Ischemic Stroke in Pregnancy: Two Case Reports and a Systematic Review of the Literature. Ryman KM; Pace WD; Smith S; Fontaine GV Pharmacotherapy; 2019 Jul; 39(7):767-774. PubMed ID: 31077601 [TBL] [Abstract][Full Text] [Related]
13. Administration of intravenous tissue plasminogen activator in a pediatric patient with acute ischemic stroke. Shuayto MI; Lopez JI; Greiner F J Child Neurol; 2006 Jul; 21(7):604-6. PubMed ID: 16970853 [TBL] [Abstract][Full Text] [Related]
20. Doubts, fears and misconceptions. What is the future of thrombolysis in acute stroke? Barber PA; Hill MD; Demchuk AM; Buchan AM Can J Neurol Sci; 2000 Nov; 27(4):283-7. PubMed ID: 11097516 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]